Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Phase I Studies : Relapsed or refractory solid tumors, including CNS tumors
This is a phase I study of a new drug, AMG 386. This drug is a in a class of drugs called angiopoietin neutralizing peptibodies, which is thought to work by regulating blood vessel growth of tumors by inhibiting the angiopoietin pathway. Part 1 will include children with non-CNS solid tumors that have failed previous treatment(s). Part 1 will be done to find the highest safe dose (called the “maximum tolerated dose or MTD”). Part 2 will evaluate the MTD in children with CNS tumors that are refractory (do not respond to treatment) or recurrent (come back). AMG 386 is given by weekly IV infusion. Biology and x-ray research studies are also performed. This study will last 5 years.
For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).
Wayne Furman, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
Referring or consulting physicians only: email@example.com
For all other inquiries about St. Jude Children's Research Hospital studies: firstname.lastname@example.org
The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.